Can an epigenetic pill boost a cancer radiation treatment?

NCT ID NCT05178693

Recruiting now Disease control Sponsor: Imperial College London Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests whether a drug called ASTX727 can help a radiation therapy called Lutathera work better for people with metastatic neuroendocrine tumors. The idea is that ASTX727 may turn back on a receptor on tumor cells that Lutathera needs to target. About 27 participants will take ASTX727 for five days before receiving Lutathera, and researchers will use special scans to see if the receptor reappears.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ASTX727 (cedazuridine and decitabine) and Lutathera (lutetium Lu 177 dotatate)
What this could lead to: If it works, this could make Lutathera more effective for more patients with neuroendocrine tumors by reactivating a key receptor.
What could go wrong: This is a very early Phase 1 trial with only 27 people, so it may not show clear benefit. The combination could also cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROENDOCRINE TUMORS

Contacts and locations

Locations

Hammersmith Hospital
RECRUITING

London, London, City of, W12 0HS, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.